These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3186084)

  • 1. Improved sensitivity in bone scintigraphy using quantitative spinal profile analysis.
    Parker D; Hart GC
    Nucl Med Commun; 1988 Sep; 9(9):631-7. PubMed ID: 3186084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the performance and interpretation of bone scans.
    Muroff LR
    Clin Nucl Med; 1981 Oct; 6(10S):P68-76. PubMed ID: 6271444
    [No Abstract]   [Full Text] [Related]  

  • 3. Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.
    Anand A; Morris MJ; Kaboteh R; Båth L; Sadik M; Gjertsson P; Lomsky M; Edenbrandt L; Minarik D; Bjartell A
    J Nucl Med; 2016 Jan; 57(1):41-5. PubMed ID: 26315832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Local bone pain and osseous scintigraphic findings in patients with metastatic bone tumor].
    Imaeda T; Iinuma G; Hirota K; Inoue A; Sone Y; Seki M; Suzuki M; Doi H
    Kaku Igaku; 1988 Dec; 25(12):1319-27. PubMed ID: 3249457
    [No Abstract]   [Full Text] [Related]  

  • 5. The value of non-staging skeletal scintigraphy in breast cancer.
    Kunkler IH; Merrick MV
    Clin Radiol; 1986 Nov; 37(6):561-2. PubMed ID: 3098492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative bone scintigraphy: usefulness in the survey of patients treated for bone metastasis of prostatic cancer.
    Grob JC; Lallot C; Methlin G; Bollack C
    Eur Urol; 1988; 15(3-4):193-5. PubMed ID: 3145888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bone scintigraphy in bone metastases due to prostatic cancer].
    Hidaka H; Ishino Y; Nakayama C; Nakata H; Okamura T
    J UOEH; 1987 Dec; 9(4):369-77. PubMed ID: 3438611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional information from quantitative 24-hour 99mTc-MDP bone scintigraphy in patients with prostatic carcinoma.
    Sundkvist GM; Ahlgren L; Lilja B; Mattsson S
    Acta Oncol; 1991; 30(5):635-9. PubMed ID: 1892682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer.
    Pollen JJ; Witztum KF; Ashburn WL
    AJR Am J Roentgenol; 1984 Apr; 142(4):773-6. PubMed ID: 6230903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of breast carcinoma metastases in bone: relative merits of X-rays and skeletal scintigraphy.
    Perez DJ; Powles TJ; Milan J; Gazet JC; Ford HT; McCready VR; MacDonald JS; Coombes RC
    Lancet; 1983 Sep; 2(8350):613-6. PubMed ID: 6136757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative bone scintigraphy with diffuse osteoblastic breast carcinoma metastases.
    Brown B; Laorr A; Greenspan A; Stadalnik R
    Clin Nucl Med; 1994 Mar; 19(3):194-6. PubMed ID: 8033466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preserved value of bone scintigraphy for the detection of skeletal metastases in prostate cancer patients with low prostate-specific antigen levels: effect of hormonal therapy and poor histologic differentiation.
    Caglar M; Tuncel M
    Clin Nucl Med; 2002 Jul; 27(7):532-3. PubMed ID: 12072787
    [No Abstract]   [Full Text] [Related]  

  • 13. 99mTc-antigranulocyte bone marrow scintigraphy of breast and prostate skeletal metastases.
    Limouris GS; Voliotopoulos V; Stavraka A; Vlahos L
    Anticancer Res; 1997; 17(3B):1615-8. PubMed ID: 9179204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of a technetium-99m bone imaging agent based on the vicinal diphosphonate 1,2-diphosphonoethyleneglycol (DPEG).
    Pauwels EK; Camps JA; Blom J; Hermans J; Kelly JD; Cumming SA; Blackburn GM; Rashid A
    Nucl Med Commun; 1985 Nov; 6(11):739-45. PubMed ID: 3831848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of raised prostatic acid phosphatase and negative skeletal scintigraphy in prostatic cancer.
    Goodman CM; Cumming JA; Ritchie AW; Chisholm GD
    Br J Urol; 1991 Jun; 67(6):622-5. PubMed ID: 2070208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bone marrow scintigraphy using radiocolloids in bone metastases. Sensitivity, specificity, reliability and indications].
    Fritz P; Adolph J; Bubeck B; Georgi P; zum Winkel K
    Rofo; 1986 Jun; 144(6):689-95. PubMed ID: 3012705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assessment of solitary hot spots of bone scintigraphy in patients with extraskeletal malignancies].
    Tomoda Y; Ishino Y; Nakata H
    Kaku Igaku; 2001 Nov; 38(6):721-6. PubMed ID: 11806083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bone scan as a tumour marker in prostatic carcinoma.
    Chisholm GD; Stone AR; Beynon LL; Merrick MV
    Eur Urol; 1982; 8(5):257-60. PubMed ID: 6288389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tracheal uptake on Tc-99m MDP bone scintigraphy can be a potential source of false-positive results in a prostate cancer patient.
    Sood A; Sethi S; Kumar R
    Clin Nucl Med; 2010 Jun; 35(6):454-5. PubMed ID: 20479601
    [No Abstract]   [Full Text] [Related]  

  • 20. [Bone imaging in the detection of skeletal metastasis].
    Shi QX
    Zhonghua Zhong Liu Za Zhi; 1989 May; 11(3):196-8. PubMed ID: 2612332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.